3 Biotechs Worthy of a Stanley Cup

If these three drug makers were hockey teams, you can bet they'd have what it takes to compete at hockey's highest level.

May 28, 2014 at 4:35PM

Now deep into the NHL's Stanley Cup Playoffs, it's clear what separates the winners from the losers. Looking at the biotech sector, some of those same traits can be the difference between winning investments and losing ones. If Isis Pharmaceuticals (NASDAQ:IONS), Ligand Pharmaceuticals (NASDAQ:LGND), and Valeant Pharmaceuticals (NYSE:VRX) were hockey teams, you just might see them win the Stanley Cup.

Shots on goal
You can't win without taking chances, and the more times you shoot the puck at the net the better your odds of scoring a goal. In health care, it's easy to take a lot of shots on goal when you have the technology to build a robust pipeline of drug candidates. Isis has such a pipeline, with 22 shots on goal in clinical trials, including 15 prospects in phase 2 trials. 

Rather than using small molecules or biologics to block disease-causing processes, Isis' pipeline uses antisense technology to treat disease at the genetic level. By directly targeting the genetic machinery underlying a disease, Isis can tailor its drug candidates to a countless number of illnesses. That has allowed management to build a portfolio of early stage candidates, and then license them to big pharma partners to aid with development costs.

While Isis' only approved drug, Kynamro, has failed to provide meaningful revenue, some of its more recent shots on goal appear to be more promising. Just this month Isis reported positive readouts on two mid-stage trials for diabetes drug ISIS-GCGR Rx and blood thinner ISIS-FXI Rx. While both shots still have a ways to go, their potential for creating value through big pharma licensing could help shareholders score.

Scoring goals may be exciting, but it won't get you very far without a goalie to protect your assets. In health care, the best way to protect your assets is with intellectual property, and Ligand Pharmaceuticals has built up a portfolio of IP that it exploited for 56% revenue growth in 2013.

Ligand's business model involves acquiring pharmaceutical assets in various medical fields and at various stages of development, and licensing them to partners willing to front development costs in exchange for royalty payments. While that means Ligand won't see big pops from blockbuster drug approvals, it also means its programs are low risk, and its operations are dirt cheap.

Sitting at a market cap of only $1.4 billion (lower than Isis, which still operates at a loss), Ligand saw operating margins of 30.5% in 2013, well above pharmaceutical powerhouses like Merck (13.5%) and Johnson and Johnson (25.7%). With growth in its Captisol product for drug delivery and $20 million in annual operating cash flow, Ligand's growth should continue.

Team synergy
A salary cap in the NHL imposes a limit on the capital that management can employ to build a team. Allstar signings may be exciting, but that leaves less cash for building a team with a deep bench. Add to that, the complexity of hockey's free flowing substitutions, and assembling a group of players who work fluidly together is critical. In the health care space, Valeant Pharmaceuticals has stood out as a master of capital allocation, and recent news has it exploiting that capital to enhance synergies.

Like Ligand, Valeant isn't interested in plowing cash into R&D. Instead, Valeant is focused on making big-name acquisitions to grow its massive portfolio of branded prescription and over the counter products. It's forced to pony-up for companies with proven products, but smart capital allocation has unlocked value through portfolio and operational synergies. 

Valeant is looking to build an even stronger team with its plan to join Bill Ackman's Pershing Square in acquiring Botox maker Allergan. Valeant already sits atop the market leaders in dermatology products, and management sees significant synergies with Allergan's product line.

Botox, Allergan's blockbuster aesthetic and neuromodulator treatment, saw 10.8% sales growth in 2013. That organic growth, coupled with the inorganic growth from recognizing SG&A synergies and slashing R&D, could help Valeant boost Allergan's already strong 30% operating margin closer to its 88% gross margin.

The bottom line
Whether it's hockey or another hobby, look for the characteristics it takes to succeed. More often than not, you'll be able to find simple connections between those hobbies and investment-worthy companies. In this case, Isis, Ligand, and Valeant each display the traits necessary to take home hockey's Stanley Cup.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Seth Robey owns shares of Isis Pharmaceuticals. The Motley Fool recommends Isis Pharmaceuticals and Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers